Production of Rapid Diagnostic Test for human papillomavirus (HPV)
Business Model Description
Produce rapid diagnostic tests for HPV, based on biomarkers, to improve the screening of cervical cancer by supplying healthcare facilities, mid-wives and doctors (B2B model) and offering flexible payment modalities especially for smaller healthcare facilities or NGOs.
Expected Impact
The production of RDT for HPV supplying healthcare providers enables a widespread cervical cancer screening, early detection and better treatment, benefiting women's health and reducing mortality.
How is this information gathered?
Investment opportunities with potential to contribute to sustainable development are based on country-level SDG Investor Maps.
Disclaimer
UNDP, the Private Finance for the SDGs, and their affiliates (collectively “UNDP”) do not seek or solicit investment for programmes, projects, or opportunities described on this site (collectively “Programmes”) or any other Programmes, and nothing on this page should constitute a solicitation for investment. The actors listed on this site are not partners of UNDP, and their inclusion should not be construed as an endorsement or recommendation by UNDP for any relationship or investment.
The descriptions on this page are provided for informational purposes only. Only companies and enterprises that appear under the case study tab have been validated and vetted through UNDP programmes such as the Growth Stage Impact Ventures (GSIV), Business Call to Action (BCtA), or through other UN agencies. Even then, under no circumstances should their appearance on this website be construed as an endorsement for any relationship or investment. UNDP assumes no liability for investment losses directly or indirectly resulting from recommendations made, implied, or inferred by its research. Likewise, UNDP assumes no claim to investment gains directly or indirectly resulting from trading profits, investment management, or advisory fees obtained by following investment recommendations made, implied, or inferred by its research.
Investment involves risk, and all investments should be made with the supervision of a professional investment manager or advisor. The materials on the website are not an offer to sell or a solicitation of an offer to buy any investment, security, or commodity, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction.
Country & Regions
- Senegal: Dakar
- Senegal: Nord
- Senegal: Centre
- Senegal: Sud
Sector Classification
Health Care
Development need
Despite progress, Senegal ranks 115th out of 195 on the Global Health Security Index, facing limited healthcare infrastructures and capacity, disrupted drug supply, and a health budget below WHO standards. Access and quality of care remain major challenges, while both infectious and non-communicable diseases are rising (1, 2, 3, 8).
Policy priority
The National Development Strategy 2025-2029 supports the development of a performing and accessible healthcare system through the diversification of the quality services offer and a better governance. Similarly, the Plan National de Développement Sanitaire et Social (PNDSS) targets the strengthening of the sector's governance and financing and development of services (2, 3).
Gender inequalities and marginalization issues
The majority of the healthcare services are concentrated in urban areas, specifically in Dakar. On the contrary, access to healthcare is challenging in rural areas due to the lack of healthcare infrastructure. For instance, the regions of Kédougou, Kaffrine and Sédhiou do not have an hospitals. In addition, women face issues in accessing to healthcare, including linked to financial, geographical accessibility, or obtaining permission to seek care. Finally, poorer households have difficulties baring the costs of care, when services are available (2, 3, 4, 5, 6).
Investment opportunities introduction
Senegal’s healthcare sector offers high-impact investment potential. With a growing population and the unequal distribution of healthcare infrastructure and the quality of medical facilities across the national territory, there is strong demand for investments in health facility upgrades, rural service expansion, and innovative solutions (2,6).
Key bottlenecks introduction
Senegal’s health system struggles with key constraints such as low health spending. Community‑based insurance enrolment remains low and the Universal health coverage is not fully implemented. This limits financial protection and increases households out of pocket expenses, above 80%, limiting access to quality healthcare (2, 3, 5, 7).
Medical Technology
Development need
Essential drug availability remains a challenge in Senegal, with frequent stockouts and limited local production. Reliance on imports is high, for around 95% of the needs, which contributes to the development of an illicit drug market. Similarly, gaps in the vaccine supply chain, such as lack of adapted storage capacity, affects the vaccines quality and supply (2, 3, 5, 9).
Policy priority
The National Development Strategy aims to strengthen pharmaceutical sovereignty through local production, enhanced regulation, and research. The PNDSS targets the reinforcement of the drug and other essential products availability throughout the healthcare system and the reinforcement of the quality assurance system (2,3).
Gender inequalities and marginalization issues
Person leaving with HIV/AIDS and tuberculosis are particularly affected by lack of drug availability. Indeed, in Senegal, only 4 out of the 26 essential drugs for HIV are tracked, enabling a regular supply. Similarly, children are also particularly affected by drugs and vaccines unavailability. It has been reported that not all health facilities providing infant immunization services had all the basic vaccines available (5, 10).
Investment opportunities introduction
Structuring investments can be made in drugs, vaccines and other essential medical products production, as Senegal ambitions to meet 30% of its drug needs through local production by 2029. It is the first francophone African country to reach the WHO Maturity Level 3 for drug regulation (3, 9).
Key bottlenecks introduction
Key challenges include lack of quality data, limited staff capacity in quantification and planning, absence of a formal national coordination framework for all the supply chain actors, and no comprehensive national supply plan (2).
Medical Equipment and Supplies
Pipeline Opportunity
Production of Rapid Diagnostic Test for human papillomavirus (HPV)
Produce rapid diagnostic tests for HPV, based on biomarkers, to improve the screening of cervical cancer by supplying healthcare facilities, mid-wives and doctors (B2B model) and offering flexible payment modalities especially for smaller healthcare facilities or NGOs.
Business Case
Market Size and Environment
< USD 50 million
5% - 10%
The Government aims at having 50% of women aged between 25 and 69 years old screened by 2029 (14).
Senegal medical device market is estimated to reach USD 24,55 million by 2030 (28).
Senegal's medical device market is expected to grow at a CAGR of 6.56% from 2025 to 2030 (28).
Indicative Return
10% - 15%
ROI is based on a stakeholder experience in the production of rapid diagnostic tests sold to an existing healthcare facility network across several countries including Senegal (12).
Investment Timeframe
Short Term (0–5 years)
Investors return on investment can be as short as less than a year (12).
Ticket Size
USD 1 million - USD 10 million
Market Risks & Scale Obstacles
Market - Highly Regulated
Impact Case
Sustainable Development Need
In Senegal, prevalence of cervical cancer is high with 2,064 new cases and 1,327 deaths in 2022. Cervical cancer presents the highest incidence and mortality rates. However, only 10% of women between 30-49 years old benefited from a screening exam for cervical cancer (2,14,15,16).
A study at the Dalal Jamm hospital showed that 70% of cancer treated were diagnosed at an advanced stage, diminishing the patients chances of survival. Yet, cervical cancer is often caused by a persistent high risk human papillomavirus (HPV) infection detectable at early stages (14, 15).
For low or middle income countries, the price of HPV diagnostic tests are a barrier to their widespread use (17).
Gender & Marginalisation
In Senegal, women are more affected by cancer than men. In addition, breast and cervical cancers, specific to women, are the most common types of cancer. Cervical cancer affect the social status of women and might isolate them due to societal perceptions (2, 18).
HIV patients have a risk to develop a cervical cancer six times higher than non-affected women, increasing their vulnerability (14).
Most healthcare facilities offering cancer screening services are located in Dakar and Thies, leaving patients in the rest of the territory out of reach (14).
Expected Development Outcome
HPV rapid diagnostic tests enable the early detection of cancer which is key to support a higher survival rate and better recovery chances for the patients. The availability of rapid diagnostic tests will contribute to the Government objective of 70% early detection of cancers (14).
The production of rapid diagnostic tests will support the Government's objective of establishing a cervical cancer screening for 50% of women aged between 25 and 69 years old by 2029, through the scale up of HPV tests, recognized as a high preforming method by WHO (14, 19).
Local production of rapid HPV tests will lower healthcare costs and make screening more accessible nationwide. These tests are faster than the traditional Visual Inspection with Acetic Acid (VIA) method, allowing more patients to be screened efficiently (12, 18).
Gender & Marginalisation
Producing rapid diagnostic tests will support the Government’s strategy of decentralizing cancer care and help ensure nationwide availability, in line with WHO recommendations for HPV testing in areas with limited access to basic healthcare, such as rural Senegal (14, 16).
More generally, HPV tests enable an reliable and rapid early detection of precancerous lesions and their treatment giving women better recovery chances and lowering their cancer mortality rate. Therefore, developing rapid diagnostic HPV tests contribute to a fairer healthcare system for women (16).
Given that rapid diagnostic tests are faster to perform than the traditional VIA method, it enables to treat more patient in the same amount of time, therefore offering more opportunities to HIV patients to access cervical cancer screening, if they are targeted beneficiaries (18).
Primary SDGs addressed
3.4.1 Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease
3.8.1 Coverage of essential health services
In 2021, the mortality rate caused by cardiovascular disease, cancer, diabetes or chronic respiratory disease was of 21.4 in 2021 (20).
Senegal presented a universal health coverage service coverage index of 50 in 2021 (20).
The Government aims at reducing the cancer mortality to 5,919 by 2029 from 7,893 deaths in 2024 (14).
N/A
Secondary SDGs addressed
Directly impacted stakeholders
People
Gender inequality and/or marginalization
Corporates
Public sector
Indirectly impacted stakeholders
People
Gender inequality and/or marginalization
Corporates
Public sector
Outcome Risks
If not managed properly, the increase in HPV test production and use might increase the environmental risks linked to improper medical waste disposal.
If key components must be imported, shortages or price fluctuations could disrupt production and test supply to healthcare facilities.
Gender inequality and/or marginalization risk: If not specifically targeted rural women and women living with HIV might still face barriers to accessing tests and early diagnosis.
Impact Risks
The cost of the HPV rapid diagnostic test might still be too high for poorest rural households, therefore not improving their access to cervical cancer screening.
Social and cultural norms shaping women’s autonomy, mobility and health-related decision making may reduce the expected impact. Cultural expectations can further restrict women’s ability or willingness to seek healthcare or adopt new practices.
Gender inequality and/or marginalization risk: Without a focus on expanding access to women in rural areas and HIV patients, increased test production may not reach everyone and the most vulnerable.
Impact Classification
What
Improved women health and decreased mortality rate of cervical cancer through increased early screening.
Who
Women, women in rural and remote areas and women living with HIV.
Risk
Exclusion of rural, remote women, women living with HIV, test's high cost for patients and social constraints could limit usage, increased pollution and supply disruptions are possible.
Contribution
Rapid diagnostic tests for HPV will contribute to the Government objective of reaching 70% of early cancer detection (14).
How Much
A regular cervical cancer screening following WHO recommendations can reduce the risks of advanced cancer by 90% on average in women aged from 35 to 64 years old (21).
Impact Thesis
The production of RDT for HPV supplying healthcare providers enables a widespread cervical cancer screening, early detection and better treatment, benefiting women's health and reducing mortality.
Enabling Environment
Policy Environment
Stratégie Nationale de Développement 2025-2029: sets the objective of an enhanced fight against non-communicable diseases, including through the upgrade of medical equipment, facilities, and services (3).
Plan National de Développement Sanitaire et Social 2019-1018: aims to improve the prevention and treatment of gynecologic cancers, including cervical cancer, to enhance maternal health, while also strengthening early detection and prevention of non-communicable diseases (2).
Plan National de Lutte contre le Cancer 2025-2029: aims at reducing cancer mortality of 25% by 2029 through equitable access to cancer prevention, early detection and treatment services. It highlight early detection as a strategic objective (14).
Financial Environment
Financial incentives: FONSIS offers investment support to projects in the fields of healthcare and pharmaceuticals with minority participation (private equity) through his funds and technical assistance to SMEs for project bankability. It supported an injectable solution production factory (12, 24).
Fiscal incentives: The new Investment Code grants VAT suspension and refund (12–24 months), plus tariff exemptions for 3 years in Dakar/Thies and 5 years elsewhere for SME investments over USD 26,600. Strategic projects may receive additional government-negotiated benefits (25).
Fiscal incentives: Investments in Special Economic Zones benefit from duties and tax exemptions on production equipment for 3 years, VAT suspension on goods and services linked to production and tax credit of 40% on investment (26).
Other incentives: Through the African Epidemic Resilience Center (CARE) and MADIBA training programs, the Institute Pasteur de Dakar is preparing the next generation of biomedical leaders in Africa (13).
Regulatory Environment
Loi n°2023-06 du 13 juin 2023 relative aux médicaments, aux autres produits de santé et à la pharmacie: sets that the commercialization of in vitro diagnostic medical device is a monopoly of pharmacopeia and requires the activities to be led by a pharmacist holding a recognized degree (22).
Decret n°2023-2419 du 27 decembre 2023: sets that the production of medical devices, including for diagnostic tests, should be authorized by the Ministry of Health, the license granted by the pharmaceutical regulatory authority for 5 years (renewable) and sets the standards for device (23).
Marketplace Participants
Private Sector
Askcare, DIATROPIX, Meditechs, Sénégalaise des Systèmes Médicaux (SSM), MN Distribution SARL.
Government
Ministry of Health and Social Action, Senegalese Pharmaceutical Regulatory Agency.
Multilaterals
World Bank, World Health Organization, Unitaid.
Non-Profit
Foundation for Innovative New Diagnostics (FIND), IRD, Ligue contre le cancer Senegal.
Target Locations
Senegal: Dakar
Senegal: Nord
Senegal: Centre
Senegal: Sud
References
- (1) GHS Index Country. 2021. Senegal. https://ghsindex.org/country/senegal/.
- (2) Ministère de la Santé et de l’Action sociale. 2019. Plan National de Développement Sanitaire et Social (PNDSS) 2019-1028. https://www.sante.gouv.sn/sites/default/files/1%20MSAS%20PNDSS%202019%202028%20Version%20Finale.pdf.
- (3) République du Sénégal. 2024. Stratégie Nationale de Développement 2025-2029. https://www.economie.gouv.sn/sites/default/files/2025-04/snd.pdf.
- (4) International Journal of Environmental Research and Public Health. 2023. Utilization of Proximate Healthcare Facilities and Children’s Wait Times in Senegal: An IV-Tobit Analysis. https://pmc.ncbi.nlm.nih.gov/articles/PMC10650125/
- (5) Health Policy Open. 2020. An assessment of the core capacities of the Senegalese health system to deliver Universal Health Coverage. https://www.sciencedirect.com/science/article/pii/S2590229620300101.
- (6) World Bank. 2025. Etude Institutionnelle du Système de Santé et Cartographie des Cas d'Usage de la Télémédecine Sénégal. https://documents1.worldbank.org/curated/en/099011725203524300/pdf/P175075-fd0a192c-785e-45f0-a1ee-21a19fb870cd.pdf.
- (7) World Bank. Data. https://data.worldbank.org/indicator/SH.XPD.OOPC.PP.CD?locations=SN.
- (8) OMS. 2024.Stratégie de Coopération de l’OMS avec le Sénégal 2024–2028. https://iris.who.int/bitstream/handle/10665/376620/978920313922-fre.pdf?sequence=1.
- (9) Africa 24. 2025. Afrique – Réglementation des médicaments : le Sénégal vise le niveau de maturité 4 de l’OMS. https://africa24tv.com/afrique-reglementation-des-medicaments-le-senegal-vise-le-niveau-de-maturite-4-de-loms#:~:text=%C3%80%20l%27instar%20de%20nombreux,d%27une%20industrie%20pharmaceutique%20locale.
- (10) ENDA Santé. 2024. Plaidoyer national sur l’accès aux médicaments au Sénégal : défis et perspectives. https://www.enda-sante.org/plaidoyer-national-sur-lacces-aux-medicaments-au-senegal-defis-et-perspectives/.
- (11) Askcare website. https://askcare-health.com/qui-sommes-nous/
- (12) Stakeholder consultations hold in October 2025.
- (13) Unitaid. 2025. Au Sénégal, un site de production de tests de diagnostic rapide renforce la souveraineté sanitaire de l’Afrique. https://unitaid.org/fr/news-blog/au-senegal-un-site-de-production-de-tests-de-diagnostic-rapide-renforce-la-souverainete-sanitaire-de-lafrique/#:~:text=Face%20%C3%A0%20la%20baisse%20de,et%20de%20la%20fi%C3%A8vre%20jaune
- (14) Ministère de la Santé et de l’Action Sociale. 2025. Plan National de Lutte contre le Cancer 2025-2029. https://www.iccp-portal.org/sites/default/files/2025-04/PLAN%20CANCER%20V7-04-2025%20VF.pdf
- (15) Ministère de la Santé et de l’Action Sociale. 2024. Normes et Protocoles de Dépistage des Lésions Précancereuses du Cold de l’Utérus et de Détéction Précoce du Cancer du Sein. https://www.sante.gouv.sn/sites/default/files/PNP%20DEPISTAGE%20KCS.pdf
- (16) Journal Africain des cas cliniques et revues. 2023. Bilan preliminaire d’activite de test au HPV dans le depistage du cancer du col de l’uterus en milieu rural, cas du district sanitaire de Fatick. https://jaccrafrica.com/assets/files/018l01050424v8n2_a_mihimit_et_al._bilan_preliminaire_hpv.pdf
- (17) Fortune Business Insights. 2024. Tests HPV et marché des tests PAP. https://www.fortunebusinessinsights.com/fr/hpv-testing-and-pap-test-market-112814
- (18) Université Paris Cité. 2021. Dépistage opportuniste du cancer du col par test HPV dans les pays a faibles et moyens revenus: exemples du Burkina Faso et de la Côte d’Ivoire. https://theses.hal.science/tel-04611785v1/file/Mensah_Keitly_va2.pdf
- (19) OMS. 2022. Stratégie Mondiale en vue d’accélérer l’élimination du cancer du Cal de l’utérus en tant que problème de santé publique. https://iris.who.int/server/api/core/bitstreams/96b1ee46-ab05-4e35-b4b0-cf84c8bce41d/content "20) UN Department of Economics and Social Affairs. Statistics, SDG Indicators Database, Senegal. https://unstats.un.org/sdgs/dataportal/database " "21) Marie Stopes Senegal. Dépistage du cancer du col de l’uterus. https://www.mariestopes.sn/nos-services/sante-sexuelle-et-de-la-reproduction/depistage-du-cancer-du-col-de-luterus/" "22) Republique de Senegal. 2023. Loi n° 2023-06 du 13 juin 2023 relative aux médicaments, aux autres produits de santé et à la pharmacie. https://arp.sn/wp-content/uploads/2024/04/Loi-n%C2%B02023-06-du-13-juin-2023-relative-aux-medicaments-aux-autres-produits-de-sante-et-a-la-pharmacie.pdf"
- (23) Republique du Senegal. 2023. Decret n°2023-2419 du 27 decembre 2023 fixant les conditions de fabrication, d’importation, d’enregistrement, d’exportation et de distribution des dispositifs medicaux. https://arp.sn/wp-content/uploads/2024/04/Decret-n%C2%B0-2023-2419-du-27-decembre-2023_Dispositifs-medicaux.pdf
- (24) FONSIS website. https://www.fonsis.org/fr/sante-et-pharma/
- (25) République du Sénégal. 2025. Code des Investissements. https://www.finances.gouv.sn/app/uploads/Code-des-Investissements.pdf
- (26) APIX. 2025. Investor's guide to Senegal. https://static.myqrcode.mobi/user-media-prod%2FLeGuideDeL-InvestisseurAuSENEGAL_EN-1-_compressed-1_6f133ca2_kr33w4
- (27) République du Sénégal. 2020. Plan National d'Amenagement et de Développement du Territoire (PNADT) Horizon 2035, Rapport Final. https://anat.sn/agence-nationale-de-lamenagement-du-territoire-anat-senegal/les-realisations-de-lagence-anat/plan-national-damenagement-et-de-developpement-territorial-du-senegal-pnadt-anat/quest-ce-que-le-plan-national-damenagement-et-de-developpement-territorial-du-senegal-pnadt/
- (28) Statista. 2025. Other Medical Devices - Senegal. https://www.statista.com/outlook/hmo/medical-technology/medical-devices/other-medical-devices/senegal?srsltid=AfmBOoooqsdl2R8RTn_NGf1Xw_l4bcdaXCXO5OQZrG5bV75YzvU8Hp6l
- (38) (enter text)
- (39) (enter text)
- (40) (enter text)
- (21) ANEP Company. https://www.anepcompany.com/fr/accueil-m1.html "22) AgriArt. 2023. Senegal:À la découverte de Anep Company qui fait environ 1M€ en CA dans l'exportation de mangues. https://www.youtube.com/watch?v=bUDozWIWSck "
- (23) Trade for Development News. 2017. Women at the helm of Senegal’s burgeoning mango industry. https://trade4devnews.enhancedif.org/en/impact-story/women-helm-senegals-burgeoning-mango-industry
- (24) Intracen. 2025. With farm co-ops, Senegal improves its agri-food value chains. https://www.intracen.org/news-and-events/news/with-farm-co-ops-senegal-improves-its-agri-food-value-chains
- (25) Mordor Intelligence. 2024. Mango Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2030). https://www.mordorintelligence.com/industry-reports/mango-market.
- (26) West Africa Connect. 2022. West Africa Competitiveness Programme – Regional Investment Profile (Summary): Mango Value Chain. https://westafricaconnect.com/wp-content/uploads/2022/08/Mango-ECOWAS-Investment-brochure-EN.pdf
- (27) WITS. 2023. Senegal Guavas, mangoes and mangosteens, fresh or dried exports by country in 2023. https://wits.worldbank.org/trade/comtrade/en/country/SEN/year/2023/tradeflow/Exports/partner/ALL/product/080450?
- (28) Sense. 2020. Business Case: Modern high yielding export mango orchard. https://timeforsense.com/wp-content/uploads/2020/12/201204-SVC-Export-Mango-Farm.pdf
- (29) Foodrise. 2017. Mango Loss and Waste in Senegal. https://foodrise.org.uk/wp-content/uploads/2017/05/Lost-Potential_Mango-Loss-and-Waste-in-Senegal_Feedback-final.pdf
- (30) Coraf. 2019. Fruit flies: when mango producers find their smile again. https://www.coraf.org/actualite/mouches-de-fruits-quand-les-producteurs-de-mangues-retrouvent-leur-sourire?locale=en
- (31) GIZ. 2021. Sector Brief Senegal: Mangoes. https://www.giz.de/en/downloads/SectorBrief_Senegal_Mango.pdf
- (32) Agence Ecofin. 2025. Sénégal : la filière mangue vise un rebond à l’export après 3 ans de baisse consécutive. https://www.agenceecofin.com/actualites-agro/1006-129054-senegal-la-filiere-mangue-vise-un-rebond-a-l-export-apres-3-ans-de-baisse-consecutive
- (33) Cirad. 2017. Le système sociotechnique associé à la mangue au Sénégal. Pré-diagnostic. https://agritrop.cirad.fr/592209/
- (34) HAL. 2024. The role of farming systems in the adoption of pest management practices: the case of the oriental fruit fly Bactrocera dorsalis in mango orchards in Senegal. https://hal.science/hal-05182486v1
- (35) UQAC. 2020. L’importance de l’innovation agroalimentaire en Afrique : cas de la mangue au Sénégal. https://constellation.uqac.ca/id/eprint/5934/#:~:text=R%C3%A9sum%C3%A9,du%20secteur%20agroalimentaire%20une%20priorit%C3%A9.
- (36) RSE Senegal. 2021. MANGUE- La filière mangue génère 12.000 emplois et 16 milliards Cfa de revenu annuel d’exportation. https://www.forumrsesn.org/2021/07/15/mangue-la-fili%C3%A8re-mangue-g%C3%A9n%C3%A8re-12-000-emplois-et-16-milliards-cfa-de-revenu-annuel-d-exportation/
- (37) UN Department of Economics and Social Affairs. Statistics, SDG Indicators Database, Senegal. https://unstats.un.org/sdgs/dataportal/database
- (38) ANSD. 2025. Enquête nationale sur l’Emploi au Sénégal (ENES) Deuxième trimestre 2025. https://www.ansd.sn/sites/default/files/2025-09/Rapport%20ENEST22025.pdf
- (39) CGIAR-AICCRA. 2024. Innovation challenge spark ideas to solve post-harvest losses in Senegal. https://alliancebioversityciat.org/stories/innovation-challenge-spark-ideas-solve-post-harvest-losses-senegal?.com. "40) Sense. 2020. Senegal Value Chain Study- Mango Prepared for: RVO Netherlands Enterprise Agency. https://timeforsense.com/wp-content/uploads/2020/12/201202-SVC-Mango-.pdf" "41) Sense. 2020. Senegal Value Chain Study- Mango Prepared for: RVO Netherlands Enterprise Agency. https://timeforsense.com/wp-content/uploads/2020/12/201202-SVC-Mango-.pdf" "42) Republique de Senegal. 1966. LOI N° 66-48 DU 27 MAI 1966 RELATIVE AU CONTROLE DES PRODUITS ALIMENTAIRES ET A LA REPRESSION DES FRAUDES. https://sherloc.unodc.org/cld/uploads/res/document/sen/loi-no-66-48-du-27-mai-1966--relative-au-controle-des-produits-alimentaires-et-a-la-repression-des-fraudes_html/Senegal_Loi_no_66-48_du_27_mai_1966.pdf" "43) Republique de Senegal. 1960. Décret n°60-121 SG – portant institution d'un contrôle Phytosanitaire des importations et des exportations des végétaux, Parties de végétaux et produits entrant au Sénégal ou en sortant. https://www.sante.gouv.sn/sites/default/files/5.%20f917f_sn3-1960-121einfuhr.pdf" "44) Republique de Senegal. 2002. LOI n° 200228 du 9 décembre 2002 autorisant le Président de la République à ratifier la version révisée de l’Accord portant Réglementation commune aux Etats membres du CILSS sur l’homologation des pesticides. https://faolex.fao.org/docs/pdf/sen144733.pdf"
- (45) Republique de Senegal. 1999. Décret n° 99-259 du 24 mars 1999 relatif au contrôle de qualité des produits horticoles. https://faolex.fao.org/docs/pdf/sen26923.pdf
- (46) Malabo Montpellier Panel. 2024. VALUE-UP: Policy Innovations to Advance Africa’s Food Processing Sector for Growth, Jobs, and Health. https://www.mamopanel.org/media/uploads/files/SENEGAL_CASE_STUDY_VALUE-UP_Policy_Innovations_to_Advance_Africas_Food_Processing_Sector_for_Growth_Jobs_and_Health.pdf "47) PWC. 2024. Senegal https://taxsummaries.pwc.com/senegal/corporate/tax-credits-and-incentives Corporate - Tax credits and incentives. "
- (48) Fongip website. https://www.fongip.sn/ "49) Republique de Senegal. 2020. PLAN NATIONAL D’AMENAGEMENT ET DE DEVELOPPEMENT TERRITORIAL https://observatoireadl.net/wp-content/uploads/2021/10/PNADT-Synthese.pdf (PNADT) Horizon 2035"
- (50) Projet Agropole Sud website. https://agropole.sn/projet-agropole-sud/
- (51) Stakeholder consultations hold in November 2025.
- (52) La Banque Agricole website. https://www.labanqueagricole.sn/prestations-de-services-agricoles